GCC AP 0341
Latest Information Update: 27 Jun 2002
Price :
$50 *
At a glance
- Originator Mitsubishi Pharma Corporation
- Class Antiasthmatics; Small molecules
- Mechanism of Action Immunomodulators; Interleukin 5 inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- No development reported Asthma
Most Recent Events
- 06 Apr 2000 Yoshitomi is now called Welfide Corporation
- 20 Feb 1997 Preclinical development for Asthma in Japan (Unknown route)